KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Non-Current Assets (2016 - 2025)

Arbutus Biopharma's Non-Current Assets history spans 15 years, with the latest figure at $268000.0 for Q3 2025.

  • For Q3 2025, Non-Current Assets fell 96.5% year-over-year to $268000.0; the TTM value through Sep 2025 reached $5.0 million, down 89.18%, while the annual FY2024 figure was $4.4 million, 64.51% down from the prior year.
  • Non-Current Assets for Q3 2025 was $268000.0 at Arbutus Biopharma, up from $148000.0 in the prior quarter.
  • Across five years, Non-Current Assets topped out at $62.7 million in Q3 2022 and bottomed at -$126.5 million in Q3 2021.
  • The 5-year median for Non-Current Assets is $12.1 million (2023), against an average of $10.7 million.
  • The largest YoY upside for Non-Current Assets was 367.41% in 2021 against a maximum downside of 1383.07% in 2021.
  • A 5-year view of Non-Current Assets shows it stood at $43.8 million in 2021, then increased by 1.04% to $44.3 million in 2022, then crashed by 72.06% to $12.4 million in 2023, then plummeted by 64.51% to $4.4 million in 2024, then crashed by 93.9% to $268000.0 in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Non-Current Assets are $268000.0 (Q3 2025), $148000.0 (Q2 2025), and $202000.0 (Q1 2025).